{"id":"atra","safety":{"commonSideEffects":[{"rate":"5-25","effect":"Retinoic acid syndrome (RAS)"},{"rate":"25-60","effect":"Headache"},{"rate":"20-40","effect":"Fever"},{"rate":"50-80","effect":"Dry skin and mucous membranes"},{"rate":"10-20","effect":"Bone pain"},{"rate":"30-50","effect":"Elevated triglycerides"},{"rate":"5-15","effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL1631960","moleculeType":"Small molecule","molecularWeight":"767.20"},"_dailymed":{"setId":"b6b45969-a64a-4ce3-b3b6-157d2568a301","title":"ATRALIN (TRETINOIN) GEL [BAUSCH HEALTH US, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ATRA is a retinoid that acts as a ligand for nuclear retinoic acid receptors (RAR and RXR), triggering transcriptional changes that force leukemic promyelocytes to differentiate into mature granulocytes rather than proliferate. This differentiation therapy approach, often combined with arsenic trioxide, has transformed acute promyelocytic leukemia (APL) from a highly fatal disease into one of the most curable acute leukemias.","oneSentence":"ATRA (all-trans retinoic acid) promotes differentiation of acute promyelocytic leukemia cells and induces apoptosis by binding to retinoic acid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:38.341Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute promyelocytic leukemia (APL)"}]},"trialDetails":[{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT01711554","phase":"PHASE1","title":"Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-02-04","conditions":"Recurrent Neuroblastoma, Refractory Neuroblastoma","enrollment":27},{"nctId":"NCT05384821","phase":"PHASE1, PHASE2","title":"Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)","status":"RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2022-09-14","conditions":"Wilms Tumor","enrollment":28},{"nctId":"NCT07469228","phase":"PHASE1","title":"A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2025-08-04","conditions":"Acne Vulgaris","enrollment":1043},{"nctId":"NCT00026312","phase":"PHASE3","title":"Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-10-26","conditions":"Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma","enrollment":1449},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT05345002","phase":"PHASE2","title":"All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma","status":"RECRUITING","sponsor":"Stephen Bagley, MD, MSCE","startDate":"2022-11-16","conditions":"Glioma, IDH Mutation, Astrocytoma","enrollment":55},{"nctId":"NCT02339740","phase":"PHASE3","title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-07-21","conditions":"Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA","enrollment":158},{"nctId":"NCT04919369","phase":"PHASE1","title":"All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dwight Owen","startDate":"2021-10-18","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":18},{"nctId":"NCT06358677","phase":"PHASE2","title":"Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors","status":"RECRUITING","sponsor":"University of Utah","startDate":"2025-02-19","conditions":"Metastatic Solid Tumor, Locally Advanced Solid Tumor","enrollment":25},{"nctId":"NCT06484920","phase":"PHASE2","title":"A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL","status":"RECRUITING","sponsor":"Rita Assi","startDate":"2024-11-18","conditions":"Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma","enrollment":24},{"nctId":"NCT07366229","phase":"PHASE2","title":"Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen People's Hospital","startDate":"2025-12-30","conditions":"Acne","enrollment":196},{"nctId":"NCT05553782","phase":"EARLY_PHASE1","title":"Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-11-01","conditions":"Salivary Gland Cancer, Adenoid Cystic Carcinoma of the Salivary Gland, Squamous Cell Carcinoma of Head and Neck","enrollment":30},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":99},{"nctId":"NCT07345507","phase":"NA","title":"Comparison of Efficacy of Metformin Gel 30% vs Triple Combination Cream (Hydroquinone 4%, Flucinolone Acetonide 0.01%, Tretinoin 0.025%) in Treatment of Melasma in Tertiary Care Hospital Karachi","status":"COMPLETED","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2025-02-01","conditions":"Melasma","enrollment":34},{"nctId":"NCT07355855","phase":"PHASE2","title":"A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01","conditions":"Rhabdomyosarcoma","enrollment":106},{"nctId":"NCT07348107","phase":"PHASE1","title":"ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Daniel Breadner","startDate":"2026-02-15","conditions":"Advanced Pancreatic Ductal Adenocarcinoma","enrollment":10},{"nctId":"NCT04241276","phase":"PHASE2","title":"A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2020-04-30","conditions":"Pancreatic Cancer","enrollment":170},{"nctId":"NCT07296445","phase":"PHASE3","title":"A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)","status":"NOT_YET_RECRUITING","sponsor":"SDK Therapeutics, Inc.","startDate":"2026-01","conditions":"Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA","enrollment":120},{"nctId":"NCT04113863","phase":"PHASE2","title":"Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2019-06-18","conditions":"Breast Neoplasm Female","enrollment":76},{"nctId":"NCT01409161","phase":"PHASE2","title":"Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-10-05","conditions":"Acute Promyelocytic Leukemia With PML-RARA","enrollment":151},{"nctId":"NCT05493280","phase":"NA","title":"Fractionated 1927nm Laser for Hyperpigmentation in Fitzpatrick Skin Phototypes V and VI","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-11-14","conditions":"Hyperpigmentation","enrollment":15},{"nctId":"NCT07278908","phase":"PHASE2, PHASE3","title":"Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12","conditions":"ITP - Immune Thrombocytopenia","enrollment":248},{"nctId":"NCT02938858","phase":"","title":"French Registry of First-line Treatment of Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2015-10","conditions":"Acute Promyelocytic Leukemia","enrollment":400},{"nctId":"NCT06439888","phase":"PHASE1, PHASE2","title":"Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2024-07-11","conditions":"Oligometastatic Disease, Solid Tumor, Adult","enrollment":58},{"nctId":"NCT06706401","phase":"PHASE3","title":"Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2025-02-20","conditions":"Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer","enrollment":460},{"nctId":"NCT06731140","phase":"PHASE2","title":"Reverse HER2-negative Immune Resistant Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-12","conditions":"HER2 Negative Breast Cancer","enrollment":10},{"nctId":"NCT01857934","phase":"PHASE2","title":"Therapy for Children With Advanced Stage Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-07-05","conditions":"Neuroblastoma","enrollment":153},{"nctId":"NCT02712905","phase":"PHASE1, PHASE2","title":"An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2016-05-05","conditions":"Solid Tumors and Hematologic Malignancy","enrollment":116},{"nctId":"NCT04303169","phase":"PHASE1, PHASE2","title":"Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-06-26","conditions":"Melanoma","enrollment":146},{"nctId":"NCT04385277","phase":"PHASE2","title":"Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-12-31","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":41},{"nctId":"NCT03786783","phase":"PHASE2","title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-04","conditions":"Ganglioneuroblastoma, High Risk Neuroblastoma","enrollment":42},{"nctId":"NCT06528769","phase":"PHASE2","title":"Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma","status":"RECRUITING","sponsor":"Gabriel Tinoco","startDate":"2025-09-10","conditions":"Leiomyosarcoma, Sarcoma","enrollment":16},{"nctId":"NCT07187505","phase":"NA","title":"Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anhui Medical University","startDate":"2025-07-01","conditions":"Acute Promyelocytic Leukemia (APL)","enrollment":28},{"nctId":"NCT06787222","phase":"PHASE2, PHASE3","title":"Effectiveness and Safety of Zingiber Officinale Transdermal Patch for Acne Vulgaris; Study of Interleukin 1 and Skin Microbiome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hasanuddin University","startDate":"2024-11-03","conditions":"Acne Vulgaris","enrollment":26},{"nctId":"NCT05438875","phase":"PHASE3","title":"The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2022-10-12","conditions":"Purpura, Thrombocytopenic, Idiopathic","enrollment":96},{"nctId":"NCT07154030","phase":"PHASE1","title":"Efficacy Of Combined Microneedling Plus Tretinoin In Treatment Of Stria Rubra","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2025-09-05","conditions":"Striae","enrollment":300},{"nctId":"NCT04305054","phase":"PHASE1, PHASE2","title":"Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-01","conditions":"Melanoma","enrollment":315},{"nctId":"NCT04305041","phase":"PHASE1, PHASE2","title":"Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-06-26","conditions":"Melanoma","enrollment":100},{"nctId":"NCT03611595","phase":"PHASE1","title":"Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors","status":"RECRUITING","sponsor":"Peter Zage","startDate":"2018-08-28","conditions":"Solid Tumor","enrollment":18},{"nctId":"NCT07142070","phase":"NA","title":"Effect of Systemic Retinoic Acid Use on Micro Ribonucleic Acid (mRNA) Expression","status":"NOT_YET_RECRUITING","sponsor":"Medipol University","startDate":"2025-09-01","conditions":"Periodontal Diseases, Inflammation","enrollment":25},{"nctId":"NCT07137130","phase":"NA","title":"Secretome TGF Beta 3","status":"NOT_YET_RECRUITING","sponsor":"Indonesia University","startDate":"2026-02-14","conditions":"Melasma","enrollment":34},{"nctId":"NCT06371274","phase":"NA","title":"A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-10-10","conditions":"Triple-negative Breast Cancer","enrollment":29},{"nctId":"NCT07084116","phase":"PHASE2, PHASE3","title":"Evaluation of Tretinoin Cream on the Integrity of Aged Forearm Skin","status":"ENROLLING_BY_INVITATION","sponsor":"Stanford University","startDate":"2025-07-14","conditions":"Skin Tear, Solar Purpura, Dermatoporosis","enrollment":30},{"nctId":"NCT07079696","phase":"PHASE2","title":"Investigating the Therapeutic Efficacy of All-trans Retinoic Acid in Autism Spectrum Disorder Patients With 15q11-13 Duplication Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-09-01","conditions":"Dup15q Syndrome, Autism Spectrum Disorder, Therapy","enrollment":90},{"nctId":"NCT03491267","phase":"EARLY_PHASE1","title":"Study to Determine Effect of Gentle Wounding to Stimulate Hair Follicle Neogenesis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2018-01-01","conditions":"Central Centrifugal Cicatricial Alopecia (CCCA)","enrollment":24},{"nctId":"NCT00392327","phase":"PHASE3","title":"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2007-05-23","conditions":"Anaplastic Medulloblastoma, Medulloblastoma","enrollment":379},{"nctId":"NCT04687176","phase":"PHASE2","title":"Frontline Oral Arsenic Trioxide for APL","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2021-01-01","conditions":"Acute Promyelocytic Leukemia","enrollment":100},{"nctId":"NCT07015931","phase":"PHASE1, PHASE2","title":"Efficacy, Safety Profile, and Post-Acne Sequelae of 0.025% Retinoic Acid Cream vs. 0.1% Adapalene Cream in Mild Acne Vulgaris in Fitzpatrick Skin Types III-V","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2024-11-30","conditions":"Acne Vulgaris","enrollment":23},{"nctId":"NCT07012811","phase":"PHASE4","title":"Treatment of Plane Warts With Topical and Oral Retinoids","status":"COMPLETED","sponsor":"Tishreen University","startDate":"2024-02-12","conditions":"Plane Warts","enrollment":39},{"nctId":"NCT06982274","phase":"PHASE2","title":"Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia","status":"RECRUITING","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2023-10-20","conditions":"Acute Promyelocytic Leukemia (APL)","enrollment":115},{"nctId":"NCT03031249","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia","status":"ENROLLING_BY_INVITATION","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2017-02-08","conditions":"AML","enrollment":80},{"nctId":"NCT06274164","phase":"","title":"Clinical and Molecular Biomarker Studies in RAI1 (Retinoic Acid-Induced 1) -Related Disorders","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2024-03-13","conditions":"RAI1 Gene 17P11.2 Deletion+Duplication","enrollment":90},{"nctId":"NCT05999812","phase":"PHASE2","title":"Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-12-19","conditions":"Colorectal Cancer","enrollment":22},{"nctId":"NCT05259722","phase":"PHASE3","title":"A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2022-06-15","conditions":"Chronic Hand Eczema","enrollment":513},{"nctId":"NCT06925386","phase":"PHASE2","title":"The Relationship Between Microbioma Balance and Acne Vulgaris as a New Acne Treatment","status":"NOT_YET_RECRUITING","sponsor":"Universitas Padjadjaran","startDate":"2025-05-01","conditions":"Acne Vulgaris","enrollment":64},{"nctId":"NCT04797780","phase":"PHASE3","title":"Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome","status":"TERMINATED","sponsor":"Syros Pharmaceuticals","startDate":"2021-02-08","conditions":"Myelodysplastic Syndromes","enrollment":246},{"nctId":"NCT06536413","phase":"PHASE1, PHASE2","title":"ATRA and Carfilzomib in Plasma Cell Myeloma Patients","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2024-07-29","conditions":"Multiple Myeloma","enrollment":42},{"nctId":"NCT06447480","phase":"PHASE3","title":"Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2025-07-01","conditions":"Acne Vulgaris","enrollment":420},{"nctId":"NCT06879795","phase":"","title":"Retinoic Acid Therapy and Regulation of Salivary and Serum IL-1β, IL-8 and MCP-1 Levels","status":"COMPLETED","sponsor":"Medipol University","startDate":"2023-09-01","conditions":"Acne Vulgaris, Gingivitis and Periodontal Diseases, Saliva Collection","enrollment":24},{"nctId":"NCT06242288","phase":"PHASE3","title":"Correlation Between Depression Scores and Serum NF-ĸB/NLRP3 Axis, Biotinidase, and HMGB After Treatment With Isotretinoin in Patients With Acne Vulgaris","status":"COMPLETED","sponsor":"Mostafa Bahaa","startDate":"2024-01-30","conditions":"Acne Vulgaris","enrollment":40},{"nctId":"NCT02688140","phase":"PHASE3","title":"Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2016-06","conditions":"Acute Promyelocytic Leukemia","enrollment":135},{"nctId":"NCT04700176","phase":"PHASE2","title":"A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2022-05-02","conditions":"Multiple Myeloma","enrollment":1},{"nctId":"NCT06728631","phase":"PHASE2","title":"Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2020-06-30","conditions":"Oral Cavity Cancer, Premalignant Lesion","enrollment":22},{"nctId":"NCT06841952","phase":"NA","title":"Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-02-15","conditions":"AML, Adult","enrollment":158},{"nctId":"NCT06158412","phase":"PHASE2","title":"All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2023-11-22","conditions":"Multiple Myeloma in Relapse, Multiple Myeloma, Refractory","enrollment":25},{"nctId":"NCT02279095","phase":"PHASE2","title":"An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)","status":"COMPLETED","sponsor":"Clementia Pharmaceuticals Inc.","startDate":"2014-10-09","conditions":"Fibrodysplasia Ossificans Progressiva","enrollment":58},{"nctId":"NCT05881265","phase":"PHASE2","title":"Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-05-15","conditions":"APL","enrollment":30},{"nctId":"NCT06780644","phase":"NA","title":"Comparison of Effectiveness and Safety of Triple Combination Cream of Fucinolone Acetonide 0.01%, Hydroquinone 4%, Tretinoin 0.05% with Mometasone Furoate 0.1%, Hydroquinone 4%, Tretinoin 0.05% in the Treatment of Melasma","status":"NOT_YET_RECRUITING","sponsor":"Indonesia University","startDate":"2025-02-17","conditions":"Melasma","enrollment":56},{"nctId":"NCT06636981","phase":"PHASE2","title":"All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-11-04","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":129},{"nctId":"NCT02807558","phase":"PHASE2","title":"A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Syros Pharmaceuticals","startDate":"2016-09-20","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":155},{"nctId":"NCT04282668","phase":"PHASE1","title":"A Study of TAS1440 With ATRA in Subjects With r/r AML","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2020-03-15","conditions":"Acute Myeloid Leukemia","enrollment":52},{"nctId":"NCT06703047","phase":"PHASE2","title":"Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-11-20","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":180},{"nctId":"NCT06698263","phase":"PHASE4","title":"13-cis Retinoic Acid (Isotretinoin) and Sperm Production","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2025-03-01","conditions":"Men with Infertility","enrollment":100},{"nctId":"NCT06685328","phase":"NA","title":"Minimal Vitrectomy and ILM Flap with Sodium Hyaluronate Gel for MH","status":"ENROLLING_BY_INVITATION","sponsor":"Jie Zhong","startDate":"2024-11-01","conditions":"Macular Hole, Macular Hole Surgery, Idiopathic Macular Hole","enrollment":52},{"nctId":"NCT06646666","phase":"PHASE2","title":"ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-01","conditions":"B-cell Non Hodgkin Lymphoma","enrollment":35},{"nctId":"NCT01969058","phase":"PHASE2","title":"Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2014-07-02","conditions":"HIV-1 Infection","enrollment":76},{"nctId":"NCT05373901","phase":"PHASE1","title":"Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2022-06-07","conditions":"High-risk Neuroblastoma","enrollment":8},{"nctId":"NCT03200847","phase":"PHASE1, PHASE2","title":"Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-10-31","conditions":"Stage IV Melanoma, Stage III Melanoma, Advanced Melanoma","enrollment":26},{"nctId":"NCT06571721","phase":"NA","title":"The Effects of Topical Almond Oil and Tretinoin on Facial Wrinkles","status":"RECRUITING","sponsor":"Integrative Skin Science and Research","startDate":"2024-07-22","conditions":"Collagen Degeneration, Wrinkle, Pigmentation","enrollment":90},{"nctId":"NCT00555399","phase":"PHASE1, PHASE2","title":"Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-11-28","conditions":"Glioblastoma Multiforme, Anaplastic Glioma","enrollment":55},{"nctId":"NCT05482451","phase":"EARLY_PHASE1","title":"Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"China Medical University Hospital","startDate":"2021-03-01","conditions":"Effect of Drug","enrollment":10},{"nctId":"NCT06213987","phase":"PHASE3","title":"The Efficacy Tretinoin Cream in the Treatment of Axillary Hyperpigmentation Associated With Acanthosis Nigricans","status":"COMPLETED","sponsor":"Srinakharinwirot University","startDate":"2024-02-01","conditions":"Acanthosis Nigricans, Hyperpigmentation","enrollment":20},{"nctId":"NCT06544109","phase":"PHASE2, PHASE3","title":"Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients","status":"ENROLLING_BY_INVITATION","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-08-01","conditions":"Acute Promyelocytic Leukemia","enrollment":98},{"nctId":"NCT03327064","phase":"PHASE1, PHASE2","title":"A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2020-10-01","conditions":"Non-melanoma Skin Cancer","enrollment":""},{"nctId":"NCT05474859","phase":"PHASE1","title":"Subjects With Advanced or Metastatic Solid Tumor Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Xenthera, Inc.","startDate":"2024-12","conditions":"Metastatic Solid Tumor, Advanced Solid Tumor","enrollment":30},{"nctId":"NCT06516419","phase":"NA","title":"Development of Products Based on Secretom From Stem Cell Conditioned Medium for Melasma Therapy","status":"RECRUITING","sponsor":"Dr.dr.Irma Bernadette, SpKK (K)","startDate":"2024-02-13","conditions":"Melasma","enrollment":90},{"nctId":"NCT00382200","phase":"PHASE1, PHASE2","title":"Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-07","conditions":"Myelodysplastic Syndromes","enrollment":54},{"nctId":"NCT04731064","phase":"","title":"Recurrence Rate of Hemorrhoidal Disease at 10 Years and More After HAL Doppler or HAL-RAR Intervention","status":"RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2023-01-06","conditions":"Hemorrhoidal Disease","enrollment":500},{"nctId":"NCT05832320","phase":"NA","title":"Optimum Induction Therapy of Low-risk APL","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2023-01-01","conditions":"Acute Promyelocytic Leukemia, Induction Therapy, Oral","enrollment":74},{"nctId":"NCT02942758","phase":"PHASE2","title":"Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML","status":"TERMINATED","sponsor":"University Hospital Regensburg","startDate":"2017-04-10","conditions":"Acute Myeloid Leukemia","enrollment":10},{"nctId":"NCT03572387","phase":"PHASE2","title":"A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2018-08-20","conditions":"Prostatic Neoplasms, Prostate Neoplasms, Prostate Cancer","enrollment":14},{"nctId":"NCT02169609","phase":"PHASE2","title":"Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma","status":"COMPLETED","sponsor":"Fundació Sant Joan de Déu","startDate":"2014-11-26","conditions":"Neuroblastoma, Neoplasm, Residual, Effects of Immunotherapy","enrollment":24},{"nctId":"NCT04793919","phase":"PHASE2","title":"Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia","status":"RECRUITING","sponsor":"Associazione Italiana Ematologia Oncologia Pediatrica","startDate":"2019-10-09","conditions":"Acute Promyelocytic Leukemia","enrollment":89},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT01526603","phase":"NA","title":"High Dose Chemotherapy and Autologous Transplant for Neuroblastoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-03-28","conditions":"Neuroblastoma","enrollment":13},{"nctId":"NCT04548349","phase":"PHASE4","title":"Profiling the Skin Microbiome in Response to Altreno in Acne Patients","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2021-04-23","conditions":"Acne, Healthy","enrollment":25},{"nctId":"NCT05388487","phase":"PHASE1","title":"Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors","status":"UNKNOWN","sponsor":"HighField Biopharmaceuticals Corporation","startDate":"2022-02-16","conditions":"Solid Tumor, Adult","enrollment":54},{"nctId":"NCT04897490","phase":"","title":"RWE of 1st Line Treatment With ATO/ATRA for Adult APL","status":"RECRUITING","sponsor":"Grupo Argentino de Tratamiento de la Leucemia Aguda","startDate":"2021-03-01","conditions":"Promyelocytic Leukemia, Adult Acute","enrollment":50},{"nctId":"NCT06181838","phase":"NA","title":"Comparison of Quality of Life in Moderate Acne Vulgaris Patients Based on Acne-QoL-INA Using Standard Therapy With and Without Acne Lesions Extraction","status":"UNKNOWN","sponsor":"Indonesia University","startDate":"2023-08-28","conditions":"Acne Vulgaris, Quality of Life","enrollment":40}],"_emaApprovals":[],"_faersSignals":[{"count":86,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"},{"count":54,"reaction":"ACUTE PROMYELOCYTIC LEUKAEMIA DIFFERENTIATION SYNDROME"},{"count":31,"reaction":"LEUKAEMIA RECURRENT"},{"count":26,"reaction":"PYREXIA"},{"count":20,"reaction":"RESPIRATORY FAILURE"},{"count":20,"reaction":"SEPSIS"},{"count":19,"reaction":"ELECTROCARDIOGRAM QT PROLONGED"},{"count":19,"reaction":"PNEUMONIA"},{"count":17,"reaction":"ACUTE MYELOID LEUKAEMIA"},{"count":17,"reaction":"INFECTION"}],"_approvalHistory":[],"publicationCount":7442,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["all-trans retinoic acid","Tretinoin","Vesanoid®","All-trans retinoic acid","Vesanoid"],"phase":"marketed","status":"active","brandName":"ATRA","genericName":"ATRA","companyName":"South China Children's Leukemia Group","companyId":"south-china-children-s-leukemia-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ATRA (all-trans retinoic acid) induces differentiation and apoptosis of acute promyelocytic leukemia cells by binding to retinoic acid receptors and promoting maturation of abnormal myeloid precursors. Used for Acute promyelocytic leukemia (APL), particularly t(15;17) positive disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":11,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}